back to US directory
us clinical guidance

Dyslipidemia and statin-based prevention

The 2026 ACC/AHA US pathway for lipid assessment, PREVENT risk estimation, statin treatment, goals and selective nonstatin intensification.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Adults and adolescents covered by the 2026 ACC/AHA dyslipidemia guideline, spanning primary prevention, clinical ASCVD, diabetes, CKD, HIV, familial disorders, elevated triglycerides and lipoprotein(a).
sources for this section:ACC/AHA lipids 2026

The Bottom Line

  • Begin lifestyle counseling early and treat prolonged exposure to atherogenic lipoproteins as a lifetime risk; consider earlier pharmacotherapy for familial hypercholesterolemia and selected young adults.
  • For primary prevention in adults aged 30 to 79, use the AHA PREVENT-ASCVD equations rather than the older Pooled Cohort Equations, then personalize risk and selectively reclassify with coronary-artery calcium.
  • Use LDL-C and non-HDL-C goals together with the intended percentage LDL-C reduction; the exact goal depends on clinical risk and secondary-prevention status.
  • Measure lipoprotein(a) at least once in adulthood and consider apolipoprotein B when triglycerides, diabetes or low achieved LDL-C may hide residual particle-related risk.
  • Statins remain the foundation for ASCVD risk reduction.
sources for this section:ACC/AHA lipids 2026

Practical clinical workflow

1
Obtain a lipid profile and history of ASCVD, diabetes, CKD, HIV, tobacco exposure, family premature ASCVD or familial dyslipidemia; evaluate secondary causes and prior intolerance.
2
For eligible primary-prevention adults, calculate PREVENT 10-year and when relevant 30-year risk, then discuss risk enhancers and selective coronary calcium testing when it will change a decision.
3
Agree the statin intensity and LDL/non-HDL goal, explain benefits and common adverse effects, and address adherence, diet, activity, weight, blood pressure and tobacco.
4
Repeat lipids after initiation or dose adjustment at the interval in the complete guideline; assess percentage and absolute response before adding a nonstatin.
5
For clinical ASCVD or severe inherited dyslipidemia, use the guideline-defined risk category and consider evidence-based nonstatin intensification and lipid-specialist input.
sources for this section:ACC/AHA lipids 2026

Safety boundaries and escalation

  • Investigate severe muscle symptoms, weakness, dark urine or systemic illness urgently; check relevant laboratory tests rather than assuming every symptom is statin intolerance.
  • Review pregnancy, breastfeeding, liver disease, interacting medicines and product-specific warnings in current FDA labeling before starting or intensifying therapy.
  • Very high triglycerides can confer pancreatitis risk and require a dedicated evaluation rather than a routine LDL-only pathway.
  • Do not use a single calculated risk value without shared decision-making or let a low short-term estimate obscure familial hypercholesterolemia, established ASCVD or another high-risk condition.
sources for this section:ACC/AHA lipids 2026

Localization

The US 2026 guideline uses PREVENT-ASCVD, US risk categories and FDA-authorized therapies. Insurer authorization and formulary rules may affect nonstatin access but do not change the evidence-based clinical assessment.
sources for this section:ACC/AHA lipids 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2026 Guideline on the Management of DyslipidemiaDOI 10.1161/CIR.0000000000001423 路 published 2026-03-13 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.